Virtu Financial’s Allogene Therapeutics ALLO Stock Holding History

Virtu Financial’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Sell	97,591 -1,094	-1%	-$2.4K	0.01%	925
2026 Q1	$241K	Buy	98,685 +56,334	+133%	+$113K	0.01%	930
2025 Q4	$58K	Buy	42,351 +15,178	+56%	+$20K	﹤0.01%	1282
2025 Q3	$34K	Buy	27,173 +2,315	+9%	+$2.76K	﹤0.01%	1198
2025 Q2	$28K	Buy	+24,858	New	+$33K	﹤0.01%	1215
2023 Q2	–	Sell	-13,561	Closed	-$67K	–	1477
2023 Q1	$67K	Buy	+13,561	New	+$87K	0.01%	1052
2022 Q4	–	Sell	-24,128	Closed	-$261K	–	1549
2022 Q3	$261K	Buy	+24,128	New	+$328K	0.02%	723
2022 Q1	–	Sell	-35,652	Closed	-$532K	–	1461
2021 Q4	$532K	Buy	+35,652	New	+$629K	0.05%	345
2019 Q4	–	Sell	-9,027	Closed	-$246K	–	1409
2019 Q3	$246K	Buy	+9,027	New	+$257K	0.02%	857

Other funds holding ALLO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Virtu Financial's ALLO Position: Q2 2026 in Review

Virtu Financial reduced its Allogene Therapeutics (ALLO) stake by 1.1% in Q2 2026, selling an estimated $2.4K and leaving 97,591 shares worth $203K. The position accounts for 0.01% of the portfolio, ranked #925.

Virtu Financial first reported a position in ALLO in Q3 2019 and has held it in 9 quarters since. The position peaked at $532K in Q4 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

Virtu Financial held 97,591 shares of Allogene Therapeutics worth $203K as of Q2 2026.
Virtu Financial sold 1,094 Allogene Therapeutics shares in Q2 2026, an estimated $2.4K.
Allogene Therapeutics made up 0.01% of Virtu Financial's portfolio in Q2 2026, its #925 holding.
Virtu Financial first reported a position in Allogene Therapeutics in Q3 2019 and has held it in 9 quarters since.
Virtu Financial's Allogene Therapeutics position peaked at $532K in Q4 2021.
209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.